Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Shares Issued (2023 - 2025)

NewAmsterdam Pharma's Shares Issued history spans 3 years, with the latest figure at -$15.3 million for Q4 2025.

  • For Q4 2025, Shares Issued fell 215.55% year-over-year to -$15.3 million; the TTM value through Dec 2025 reached $1.6 million, down 88.1%, while the annual FY2025 figure was $1.6 million, 88.1% down from the prior year.
  • Shares Issued for Q4 2025 was -$15.3 million at NewAmsterdam Pharma, down from $16.8 million in the prior quarter.
  • Across five years, Shares Issued topped out at $16.8 million in Q3 2025 and bottomed at -$15.3 million in Q4 2025.
  • The 3-year median for Shares Issued is $1.3 million (2023), against an average of $2.0 million.
  • The largest annual shift saw Shares Issued crashed 263.93% in 2024 before it skyrocketed 28831.03% in 2025.
  • A 3-year view of Shares Issued shows it stood at $8.3 million in 2023, then skyrocketed by 59.18% to $13.3 million in 2024, then plummeted by 215.55% to -$15.3 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Shares Issued are -$15.3 million (Q4 2025), $16.8 million (Q3 2025), and -$7.7 million (Q2 2025).